Spotlight report on molecular testing in advanced lung cancer

Reports | Published: 09 Jan 2020

This spotlight audit is the first national study investigating the efficacy and outcomes of molecular testing in patients with advanced non-small-cell lung cancer (NSCLC) in England. In total 60 trusts provided data on 1,157 patients.

Some of the key findings include:

  • 83% of patients with advanced adenocarcinoma underwent molecular testing for all three of the recommended predictive biomarkers (EGFR, ALK and PD-L1).
  • 96% of molecular tests were successful in providing adequate results.
  • 11.5% of patients required second biopsies to obtain molecular results. There was an increased likelihood of patients requiring a second sampling technique if the initial attempt was through pleural biopsy or aspiration.
  • The median turnaround time from tissue acquisition to EGFR mutation result was 18 days.
  • First-line targeted therapies were received by 75% of patients following confirmation of an EGFR mutation and 58% of patients with an ALK translocation.

You can download the report here. Please note you will be prompted to register your details so you can receive updates. You may skip the registration process if you prefer.

Don’t miss out. Sign up to be notified when this resource is updated and to receive updates about other related quality improvement resources, events and news from HQIP. Or you can  .


By continuing you agree to receive emails with updates and other information from HQIP and you are confirming you are over the age of 13.

Please read our privacy policy to understand how HQIP uses the information you provide, your use of HQIP’s website and your interaction with the marketing emails to improve the relevance of the communications we send you. You can unsubscribe at any time.

I have read and agree with the contents of the privacy policy.

Spotlight report on molecular testing in advanced lung cancer